Share This Author
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
There is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition, familial hypercholesterolaemia.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels and there was evidence of a reduction in the rate of cardiovascular events.
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
The Panel proposes to identify SAMS by symptoms typical of statin myalgia and their temporal association with discontinuation and response to repetitive statin re-challenge, and recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets.
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simVastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein.
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial…
The need for early identification of HoFH patients, prompt referral to specialized centres, and early initiation of appropriate treatment is highlighted, and recommendations offer guidance for a wide spectrum of clinicians who are often the first to identify patients with suspected HoFH.
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation.
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
This consensus paper aims to improve awareness of the need for early detection and management of FH children by recommending cascade screening of families using a combined phenotypic and genotypic strategy.
A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200
- G. J. de Grooth, A. Klerkx, E. Stroes, A. Stalenhoef, J. Kastelein, J. Kuivenhoven
- BiologyJournal of Lipid Research
- 1 November 2004
The potential of CETP inhibitors to protect against atherosclerosis in the context of the current knowledge of CETp function in both rodents and humans is discussed.